Journal
MOLECULAR PHARMACEUTICS
Volume 20, Issue 11, Pages 5247-5253Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acs.molpharmaceut.3c00479
Keywords
SARS-CoV-2; vaccination; lipid nanoparticle; protein corona
Ask authors/readers for more resources
The integration of the lipid nanoparticle (LNP)-protein corona represents a groundbreaking approach in vaccine development against current and future SARS-CoV-2 variants. It offers a universal platform that can be adapted to combat unknown viruses and has the potential to address viral threats, cancer, and genetic diseases. Collaborative efforts and safety assessments are key in translating this transformative workflow from the laboratory to clinical reality.
The integration of the lipid nanoparticle (LNP)-protein corona as a pioneering approach for the development of vaccines against the present and future SARS-CoV-2 variants of concern marks a significant shift in the field. This concept holds great promise, offering a universal platform that can be adaptable to combat future pandemics caused by unknown viruses. Understanding the complex interactions among the protein corona, LNPs, and receptors is crucial for harnessing its potential. This knowledge will allow optimal vaccine formulations and improve their effectiveness. Safety assessments are essential to ensure suitability for human use, compliance with regulatory standards, and rigorous quality control in manufacturing. This transformative workflow requires collaborative efforts, expanding our foundational knowledge and translating advancements from the laboratory to clinical reality. The LNP-protein corona approach represents a paradigmatic shift with far-reaching implications. Its principles and insights can be leveraged beyond specific applications against SARS-CoV-2, enabling a universal platform for addressing viral threats, cancer, and genetic diseases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available